Compass Financial Advisors LLC increased its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 23.1% in the fourth quarter, according to its latest Form 13F filing with the Securities and Exchange Commission. The company owned his 16,657 shares of medical research company stock after purchasing an additional 3,131 shares during the quarter. Exact Sciences holds approximately 1.1% of Compass Financial Advisors LLC’s holdings, making it the 25th largest position. Compass Financial Advisors LLC’s Exact Sciences holding was valued at $825,000 at the end of the most recent quarter.
Several other institutional investors have also changed their stakes in the company. Signaturefd LLC increased his Exact Sciences stake by 17.7% in the fourth quarter. Signaturefd LLC now owns 1,126 shares of the medical research company worth $56,000 after purchasing an additional 169 shares in the previous quarter. Moody National Bank Trust Division raised his Exact Sciences stake by 3.2% in the fourth quarter. Moody National Bank Trust Division now owns 7,824 shares of the medical research company worth $387,000 after purchasing an additional 244 shares last quarter. WoodTrust Financial Corp increased its Exact Sciences stake by 1.6% in the fourth quarter. WoodTrust Financial Corp now owns 15,687 shares of the medical research company worth $777,000 after purchasing an additional 250 shares during the previous quarter. Silvant Capital Management LLC increased its Exact Sciences stake by 1.7% in the fourth quarter. Silvant Capital Management LLC now owns 16,278 shares of the medical research company worth $806,000 after purchasing an additional 270 shares during the previous quarter. Finally, Pangora Asset Management Inc. increased its Exact Sciences stake by 4.6% in the first quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company worth $509,000 after purchasing an additional 323 shares last quarter. Institutional investors and hedge funds own 90.30% of the company’s shares.
Insider trading on Exact Sciences
In other news from Exact Sciences, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction that took place on Monday, April 3rd. The shares sold at an average price of $67.19, giving her a total of $67,190.00. After the sale, the Executive Vice President now owns 86,692 shares of the Company’s stock valued at approximately $5,824,835.48. The transaction was disclosed in legal filings with the Securities and Exchange Commission which can be accessed at this link. In other news from Exact Sciences, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction that took place on Monday, April 3rd. The shares sold at an average price of $67.19, bringing her total to $67,190.00. After the sale, the Executive Vice President now owns 86,692 shares of the Company’s stock valued at approximately $5,824,835.48. The transaction was disclosed in legal filings with the Securities and Exchange Commission which can be accessed at this link. And insider Jacob A. Orville sold 5,000 shares of the company’s stock in a deal that took place on Friday, March 3rd. The shares sold for an average of $65.00, giving him a total of $325,000.00. Following the closing of the sale, the insider now owns directly his 11,423 shares in the company, valued at approximately $742,495. Please see here for the disclosure of this sale. The insider said that in the past 90 days he has sold 62,126 shares of company stock worth $3,922,776. His 1.30% of shares are now owned by insiders.
Analyst upgrades and downgrades
Several brokerage firms have recently commented on EXAS. Piper Sandler raised Exact Sciences’ price target from her $50.00 to her $70.00, giving the company a “neutral” rating in a report on Friday, March 3. SVB Leerink has raised Exact Sciences’ target price from $70.00 to $75.00, giving the company an “excellent” rating in its report on Thursday, January 12th. Robert W. Baird raised his price target on Exact Sciences from $89.00 to his $92.00, giving it an “outperform” rating in its research notes on Wednesday, Feb. 22. Canaccord Genuity Group raised its price target on Exact Sciences from $70.00 to $75.00, giving it a Buy rating in its research report on Wednesday, February 22nd. Finally, BTIG Research lowered his price target for Exact Sciences from $85.00 to $80.00, giving the company a “Buy” rating in its research report on Wednesday, February 22nd. Five analysts assigned a hold rating to the stock and eight assigned a buy rating to the company’s stock. According to MarketBeat data, Exact Sciences has a consensus rating of “moderate buy” and a consensus price target of $73.31.
Exact Sciences stock drops 0.1%
EXAS shares opened Wednesday at $63.50. His 50-day simple moving average for the stock is $65.03 and its 200-day simple moving average is $54.82. The company has a debt to equity ratio of 0.73, a current ratio of 2.38 and a quick ratio of 2.09. Exact Sciences Co. has a 12-month low of $29.27 and a 12-month high of $72.18.
Exact Sciences (NASDAQ:EXAS – Get Rating) last published its quarterly earnings data on Tuesday, February 21. The medical research firm reported his earnings per share for the quarter ($0.72), beating analyst consensus expectations ($0.90) by $0.18. Exact Sciences had a return on equity of 19.76% and a net profit margin of 29.92%. The business generated $553 million in revenue for the quarter, compared to consensus expectations of $525.61 million. At the same time last year, the business earned him an EPS of $1.28. The company’s revenue increased by 16.7% compared to the same quarter last year. As a group, Equity Research analysts expect Exact Sciences Co. to post -2.76 EPS for the current financial year.
Exact Sciences company profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company focuses on early detection and prevention of certain types of cancer. The company offers a non-invasive screening test called Cologuard for the early detection of colorectal and precancer and Oncotype DX. The company was founded on February 10, 1995 and is headquartered in Madison, Wisconsin.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to firstname.lastname@example.org.
Listen to this before considering Exact Sciences.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Exact Sciences wasn’t on the list .
Exact Sciences currently has a ‘moderate buy’ rating among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here